Pharmacosmos A/S of Denmark sells its rights to Zydus to distribute MonoFerric injectable in India and Nepal
According to the company's regulatory filing, MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are inefficient or cannot be administered or if there is a clinical need to deliver iron quickly.
admin
On Friday, Zydus Lifesciences Ltd announced that it has purchased the rights from Pharmacosmos A/S of Denmark to offer MonoFerric (iron isomaltoside) injection in India and Nepal, which is used to treat iron insufficiency in adult patients.
According to the company's regulatory filing, MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are inefficient or cannot be administered or if there is a clinical need to deliver iron quickly.
The transaction's financial specifics were kept confidential by Zydus Lifesciences.
According to Zydus Lifesciences Managing Director Dr. Sharvil Patel, iron deficiency poses a serious healthcare problem and has a greater impact on patients with CKD (chronic kidney disease) in terms of quality of life.
He stated that by doing this, these patients will have access to this crucial medicine, which will be improved by the business' "excellent last-mile delivery."
Reduce the number of infusions necessary to achieve iron correction with the MonoFerric iron isomaltoside 1,000 solution for injection/infusion, a fast, single dose IV iron (up to 20 mg/kg bodyweight).
According to the manufacturer, more than 28 million doses of MonoFerric have been given since its introduction. It is available in over 30 countries, including the US and Europe.
